Cargando…

Targeted next generation sequencing in Chinese colorectal cancer patients guided anti-EGFR treatment and facilitated precision cancer medicine

OBJECTIVE: Colorectal cancer (CRC) patients with both RAS and BRAF wild-type tumors determined by non-next generation sequencing (NGS) testing may still not respond due to the presence of additional mutated genes such as PIK3CA or PTEN. In this study, a broad, hybrid capture-based NGS assay was used...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Helei, Liu, Dong, Zhang, Chuantao, Jiang, Yanxia, Lu, Guifang, Zhou, Na, Yang, Xiaonan, Zhang, Xiaoping, Li, Zhuokun, Zhu, Hongmei, Qian, Zhaoyang, Zhang, Xiaochun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739621/ https://www.ncbi.nlm.nih.gov/pubmed/29285234 http://dx.doi.org/10.18632/oncotarget.21349

Ejemplares similares

Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay
por: Hou, Helei, et al.
Publicado: (2017)

Publisher Correction: Discovery of targetable genetic alterations in advanced non-small cell lung cancer using a next-generation sequencing-based circulating tumor DNA assay
por: Hou, Helei, et al.
Publicado: (2018)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

The efficacy and safety of apatinib for refractory malignancies: a review and meta-analysis
por: Sun, Dantong, et al.
Publicado: (2018)

Use tumor suppressor genes as biomarkers for diagnosis of non-small cell lung cancer
por: Zhang, Chuantao, et al.
Publicado: (2021)

Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis
por: Qin, Kang, et al.
Publicado: (2020)

Neoadjuvant PD-1 blockade plus chemotherapy versus chemotherapy alone in locally advanced stage II-III gastric cancer: A single-centre retrospective study
por: Zhang, Xuchen, et al.
Publicado: (2023)

KIT/PDGFRA/KDR amplification defines a novel molecular subtype of adenoid cystic carcinoma patients who may benefit from treatment with tyrosine kinase inhibitors
por: Hou, Helei, et al.
Publicado: (2020)

Concurrent TP53 mutations predict poor outcomes of EGFR-TKI treatments in Chinese patients with advanced NSCLC
por: Hou, Helei, et al.
Publicado: (2019)

Chemotherapy Alters the Phylogenetic Molecular Ecological Networks of Intestinal Microbial Communities
por: Cong, Jing, et al.
Publicado: (2019)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Role of YES1 amplification in EGFR mutation‐positive non‐small cell lung cancer: Primary resistance to afatinib in a patient
por: Tao, Junyan, et al.
Publicado: (2020)

Toward precision medicine with next-generation EGFR inhibitors in non-small-cell lung cancer
por: Yap, Timothy A, et al.
Publicado: (2014)

Anlotinib Combined with Toripalimab as Second-Line Therapy for Advanced, Relapsed Gastric or Gastroesophageal Junction Carcinoma
por: Jiang, Man, et al.
Publicado: (2022)

Progress in the treatment of solid tumors with apatinib: a systematic review
por: Zhao, Deze, et al.
Publicado: (2018)

The role of MDM2 amplification and overexpression in therapeutic resistance of malignant tumors
por: Hou, Helei, et al.
Publicado: (2019)

The role of RICTOR amplification in targeted therapy and drug resistance
por: Zhao, Deze, et al.
Publicado: (2020)

Precision immunointerception of EGFR-driven tumorigenesis for lung cancer prevention
por: Pan, Jing, et al.
Publicado: (2023)

Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence
por: Wang, Xiaochun, et al.
Publicado: (2016)

Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
por: Zhang, Jialing, et al.
Publicado: (2018)

Clinical Next Generation Sequencing for Precision Medicine in Cancer
por: Dong, Ling, et al.
Publicado: (2015)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Next-generation metabolomics in lung cancer diagnosis, treatment and precision medicine: mini review
por: Yu, Li, et al.
Publicado: (2017)

Next-generation sequencing-based identification of EGFR and NOTCH2 complementary mutations in non-small cell lung cancer
por: Niu, Lin, et al.
Publicado: (2021)

Primary resistance to first-generation EGFR-TKIs induced by MDM2 amplification in NSCLC
por: Sun, Dantong, et al.
Publicado: (2020)

Pinin facilitated proliferation and metastasis of colorectal cancer through activating EGFR/ERK signaling pathway
por: Wei, Zhigang, et al.
Publicado: (2016)

Models based on nucleic acid methylation regulators will contribute to facilitating cancer precision medicine
por: Zhang, Wen
Publicado: (2021)

The safety and serious adverse events of approved ALK inhibitors in malignancies: a meta-analysis
por: Hou, Helei, et al.
Publicado: (2019)

A Pilot Study: Changes of Gut Microbiota in Post-surgery Colorectal Cancer Patients
por: Cong, Jing, et al.
Publicado: (2018)

Cancer prevention and screening: the next step in the era of precision medicine
por: Loomans-Kropp, Holli A., et al.
Publicado: (2019)

Next-Generation EGFR Tyrosine Kinase Inhibitors for Treating EGFR-Mutant Lung Cancer beyond First Line
por: Sullivan, Ivana, et al.
Publicado: (2017)

Epidermal growth factor receptor (EGFR): A rising star in the era of precision medicine of lung cancer
por: Liu, Xiaomin, et al.
Publicado: (2017)

Apatinib in Combination with S‐1 as First‐Line Treatment in Patients with Advanced Metastatic Gastric Cancer: Results from an Open, Exploratory, Single‐Arm, Phase II Trial
por: Zhou, Na, et al.
Publicado: (2020)

Radiomics-Guided Precision Medicine Approaches for Colorectal Cancer
por: Quraishi, Mohammed I.
Publicado: (2022)

Changing paradigm of cancer therapy: precision medicine by next-generation sequencing
por: Xue, Yuan, et al.
Publicado: (2016)

Mechanisms of resistance to anti-EGFR therapy in colorectal cancer
por: Zhao, Ben, et al.
Publicado: (2016)

Integrative genomic analysis facilitates precision strategies for glioblastoma treatment
por: Chen, Danyang, et al.
Publicado: (2022)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
por: Li, Yufeng, et al.
Publicado: (2023)

Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer
por: Ciardiello, Davide, et al.
Publicado: (2021)

JMJD5 inhibits lung cancer progression by facilitating EGFR proteasomal degradation
por: Shen, Jing, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_oqupb12q7ouqhdob29q57c471n